Quantum Genomics Logo

Quantum Genomics

Biopharma developing cardiovascular treatments, now in judicial liquidation.

ALQGC | PA

Overview

Corporate Details

ISIN(s):
FR0010783837 (+4 more)
LEI:
969500TFCD8K9RPM9K97
Country:
France
Address:
6 RUE CAMBACERES, 75008 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Quantum Genomics is a biopharmaceutical company focused on developing treatments for unmet medical needs, particularly in cardiovascular diseases such as hypertension and heart failure. The company's research was centered on a novel therapeutic approach involving Brain Aminopeptidase A Inhibition (BAPAI), with its lead drug candidate being firibastat. In early 2024, Quantum Genomics acquired the company Exactcure. However, recent developments indicate that the company has subsequently filed for judicial liquidation.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-13 18:00
Post-Annual General Meeting Information
Report de l'Assemblée Générale Mixte du 30/06/2025
French 116.4 KB
2025-04-30 20:00
Earnings Release
Quantum Genomics publishes its 2024 annual financial statements and announces a…
English 206.5 KB
2025-04-30 20:00
Delisting Announcement
Quantum Genomics publie ses comptes annuels 2024 et annonce un changement de li…
French 254.0 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics fait un point sur sa situation
French 688.8 KB
2025-04-08 08:00
Delisting Announcement
Quantum Genomics provides an update on its situation
English 626.0 KB
2024-10-29 18:00
Earnings Release
Quantum Genomics publie ses résultats du 1er semestre 2024 et annonce la nomina…
French 241.2 KB
2024-09-27 08:00
Legal Proceedings Report
Quantum Genomics sécurise un financement avec le fonds Akkadian Partners Fund e…
French 74.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics reviewed its financial situation and announced that it has fil…
English 175.5 KB
2024-09-04 18:00
Legal Proceedings Report
Quantum Genomics fait un point sur sa situation financière et annonce qu'elle a…
French 150.0 KB
2024-07-03 13:00
Capital/Financing Update
BILAN SEMESTRIEL S1 DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE…
French 275.3 KB
2024-03-13 18:00
Business and Financial Review
Quantum Genomics publie ses résultats de l'exercice 2023. Le rapprochement avec…
French 193.8 KB
2024-03-13 18:00
Earnings Release
Quantum Genomics publishes its results for the 2023 financial year. The merger …
English 166.3 KB
2024-01-10 16:35
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2024-01-10 16:30
Capital/Financing Update
Bilan au 29 décembre 2023 du contrat de liquidité contracté avec la Société de …
English 297.2 KB
2023-12-14 18:05
Regulatory News Service
Quantum Genomics enters into exclusive negotiations with ExactCure
English 286.1 KB

Automate Your Workflow. Get a real-time feed of all Quantum Genomics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Quantum Genomics

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Quantum Genomics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ARROWHEAD PHARMACEUTICALS, INC. Logo
Develops RNAi medicines to silence genes causing intractable cardiometabolic and pulmonary diseases.
United States of America
ARWR
ARS Pharmaceuticals, Inc. Logo
Develops the first FDA-approved, needle-free epinephrine spray for severe allergic reactions.
United States of America
SPRY
ARTELO BIOSCIENCES, INC. Logo
Develops lipid-signaling therapeutics for cancer, pain, anxiety, and depression.
United States of America
ARTL
Artiva Biotherapeutics, Inc. Logo
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
United States of America
ARTV
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden
ACE
Ascendis Pharma A/S Logo
Biopharma using proprietary TransCon® tech to develop therapies for rare diseases & oncology.
United States of America
ASND
ASCENTAGE PHARMA GROUP INTERNATIONAL Logo
Biopharma developing small-molecule drugs for cancer, HBV, and age-related diseases.
United States of America
AAPG
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan
4886
Aspire Biopharma Holdings, Inc. Logo
Developing a nano-platform for rapid, sublingual delivery of reformulated medications.
United States of America
ASBP
ASSEMBLY BIOSCIENCES, INC. Logo
Clinical-stage biopharma developing small-molecule antivirals for herpes, HBV, and HDV.
United States of America
ASMB

Talk to a Data Expert

Have a question? We'll get back to you promptly.